 Fluorouracil
"Fluorouracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
| Descriptor ID |
D005472
|
| MeSH Number(s) |
D03.383.742.698.875.404
|
| Concept/Terms |
Fluorouracil- Fluorouracil
- 5-FU
- Fluoruracil
- 5-Fluorouracil
- 5 Fluorouracil
- 5FU
5-FU medac- 5-FU medac
- 5 FU medac
- medac Brand of Fluorouracil
5-HU Hexal- 5-HU Hexal
- 5 HU Hexal
- Hexal Brand of Fluorouracil
Adrucil- Adrucil
- Teva Brand of Fluorouracil
- Fluorouracil Teva Brand
Carac- Carac
- Dermik Brand of Fluorouracil
Efudix- Efudix
- Dermatech Brand of Fluorouracil
- Roche Brand of Fluorouracil
- Fluoro-Uracile ICN
- Fluoro Uracile ICN
- ICN Brand of Fluorouracil
- CSP Brand of Fluorouracil
- Efudex
Fluoroplex- Fluoroplex
- Flurodex
- Allergan Brand of Fluorouracil
Fluracedyl- Fluracedyl
- Pharmachemie Brand of Fluorouracil Monosodium Salt
Haemato-fu- Haemato-fu
- Haemato fu
- Haemato Brand of Fluorouracil
Neofluor- Neofluor
- Neocorp Brand of Fluorouracil
Onkofluor- Onkofluor
- Onkoworks Brand of Fluorouracil
Ribofluor- Ribofluor
- ribosepharm Brand of Fluorouracil
5-FU Lederle- 5-FU Lederle
- 5 FU Lederle
- Riemser Brand of Fluorouracil
|
Below are MeSH descriptors whose meaning is more general than "Fluorouracil".
Below are MeSH descriptors whose meaning is more specific than "Fluorouracil".
This graph shows the total number of publications written about "Fluorouracil" by people in this website by year, and whether "Fluorouracil" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 1 | 0 | 1 | | 1982 | 0 | 1 | 1 | | 1983 | 0 | 2 | 2 | | 1984 | 0 | 1 | 1 | | 1986 | 2 | 1 | 3 | | 1988 | 0 | 4 | 4 | | 1989 | 1 | 4 | 5 | | 1990 | 2 | 5 | 7 | | 1991 | 1 | 3 | 4 | | 1992 | 5 | 5 | 10 | | 1993 | 3 | 3 | 6 | | 1994 | 2 | 5 | 7 | | 1995 | 1 | 7 | 8 | | 1996 | 2 | 8 | 10 | | 1997 | 1 | 4 | 5 | | 1998 | 4 | 6 | 10 | | 1999 | 4 | 6 | 10 | | 2000 | 3 | 8 | 11 | | 2001 | 5 | 7 | 12 | | 2002 | 7 | 9 | 16 | | 2003 | 7 | 6 | 13 | | 2004 | 5 | 7 | 12 | | 2005 | 2 | 8 | 10 | | 2006 | 2 | 7 | 9 | | 2007 | 0 | 6 | 6 | | 2008 | 2 | 3 | 5 | | 2009 | 4 | 3 | 7 | | 2010 | 1 | 10 | 11 | | 2011 | 1 | 11 | 12 | | 2012 | 3 | 11 | 14 | | 2013 | 2 | 8 | 10 | | 2014 | 4 | 9 | 13 | | 2015 | 2 | 3 | 5 | | 2016 | 1 | 5 | 6 | | 2017 | 1 | 5 | 6 | | 2018 | 0 | 4 | 4 | | 2019 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Fluorouracil" by people in Profiles.
-
Catenacci DV, Tesfaye A, Tejani M, Cheung E, Eisenberg P, Scott AJ, Eng C, Hnatyszyn J, Marina N, Powers J, Wainberg Z. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun; 15(18):2073-2082.
-
Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019 07; 22(4):828-837.
-
Cheng X, Yu S, Wang Y, Cui Y, Li W, Yu Y, Tang C, Jiang H, Ji Y, Sun Y, Wang X, Shen Z, Liu F, Liu TS. The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. Gastric Cancer. 2019 05; 22(3):587-597.
-
Marco MR, Zhou L, Patil S, Marcet JE, Varma MG, Oommen S, Cataldo PA, Hunt SR, Kumar A, Herzig DO, Fichera A, Polite BN, Hyman NH, Ternent CA, Stamos MJ, Pigazzi A, Dietz D, Yakunina Y, Pelossof R, Garcia-Aguilar J. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Dis Colon Rectum. 2018 Oct; 61(10):1146-1155.
-
Xu Y, Yang X, Wang T, Yang L, He YY, Miskimins K, Qian SY. Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-?-linolenic acid peroxidation dependent mechanism. BMC Cancer. 2018 03 27; 18(1):330.
-
Maron SB, Alpert L, Kwak HA, Lomnicki S, Chase L, Xu D, O'Day E, Nagy RJ, Lanman RB, Cecchi F, Hembrough T, Schrock A, Hart J, Xiao SY, Setia N, Catenacci DVT. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 06; 8(6):696-713.
-
de W Marsh R, Talamonti MS, Baker MS, Posner M, Roggin K, Matthews J, Catenacci D, Kozloff M, Polite B, Britto M, Wang C, Kindler H. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
-
Liauw SL. A Pancreatic Predicament. Int J Radiat Oncol Biol Phys. 2017 10 01; 99(2):296-297.
-
Pei S, Kaminska ECN, Tsoukas MM. Treatment of Actinic Keratoses: A Randomized Split-Site Approach Comparison of Sequential 5-Fluorouracil and 5-Aminolevulinic Acid Photodynamic Therapy to 5-Aminolevulinic Acid Photodynamic Monotherapy. Dermatol Surg. 2017 Sep; 43(9):1170-1175.
-
Knight JC, Mosley MJ, Bravo LC, Kersemans V, Allen PD, Mukherjee S, O'Neill E, Cornelissen B. 89Zr-anti-?H2AX-TAT but not 18F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017 Nov 01; 23(21):6498-6504.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|